# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: James Madison (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN007-SYN-TD
- Date: 1774-04-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Josiah Pembroke-Achebe, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Discharge-day review after video-EEG monitoring; epilepsy and functional neurological disorder consultation today. **S**

## History of present illness

Mr. Madison is seen on the morning of discharge after 72 hours of video-EEG monitoring. Two of his usual events were recorded, the second on the third evening after a night of sleep deprivation, and he confirmed on review of the video that both were typical. His MRI last week was normal. Dr. Okafor-Haverford of neurology reviewed the recordings with him yesterday and explained the diagnosis, and the neuropsychiatric assessment on the unit found generalized anxiety and a moderate depressive episode. He says he is relieved that it is not epilepsy, though he wonders how something that feels so real could come from the mind; he asked good questions and has read the written explanation. He has had no thoughts of death or self-harm, and the rifle has been locked away with the ammunition stored separately since his first visit. He has not driven since then. **S**

| Element | Detail |
|---|---|
| Video-EEG | Two habitual events captured; normal EEG throughout both |
| MRI | Normal |
| Mood and anxiety | PHQ-9 12; GAD-7 13 |
| Safety | No suicidal thoughts; rifle locked; not driving |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired after a night of sleep deprivation; no fever |
| Cardiovascular | Negative | No palpitations, chest pain, or exertional faintness |
| Neurological | Positive | Two recorded events; no headache, weakness, or numbness |
| Psychiatric | Positive | Low mood, worry, and irritability on levetiracetam; no suicidal thoughts, elevated mood, or psychotic symptoms |

4 systems reviewed. **S**

## Current medications

- Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stop **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/68 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 54.2 kg; BMI 19.2 kg/m². All vital signs are synthetic.

PHQ-9: 12; GAD-7: 13. All results are synthetic.

## Change since baseline

- PHQ-9: 13 at baseline, 12 at this visit **S**
- GAD-7: 14 at baseline, 13 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Slight, tired, engaged |
| Neurological | Normal cranial nerves, strength, reflexes, coordination, and gait |
| Mental status | Mood "relieved but low"; affect constricted, brightening when discussing his studies; logical; no suicidal ideation; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Functional/dissociative seizures, documented by video-EEG** (F44.5). Both habitual events were recorded: eyes closed and resisting opening, fluctuating unresponsiveness for minutes, and slow side-to-side head movements, with a continuous normal waking EEG and no ictal or postictal change. With a typical history and normal interictal EEG and MRI, this meets the ILAE 'documented' level of certainty for functional/dissociative seizures. Epilepsy is excluded as the cause of these events: a focal impaired-awareness seizure would be expected to change the EEG, the eyes are usually open, and the events have not responded to levetiracetam. Syncope is excluded by the duration, the closed eyes, the normal ECG and orthostatic vital signs, and the normal EEG during unresponsiveness. Dr. Okafor-Haverford agrees and has explained the diagnosis to him. **S**
   - Diagnosis explained again today in plain words and in writing: a real and common condition in which the brain switches off awareness under strain; not epilepsy and not put on; treatable.
   - Taper levetiracetam over three weeks and stop it.
   - CBT-informed psychotherapy, twelve weekly sessions, starting in two weeks.
   - Keep the event diary and use the first-aid card.
   - Do not drive yet, including during the taper.
   - Review in six weeks.
2. **Recurrent sudden episodes of unresponsiveness** (R40.4). Explained by functional/dissociative seizures; superseded by that diagnosis. **S**
   - Managed under the functional seizure problem.
3. **Taking an antiseizure medicine without a confirmed diagnosis** (Z79.899). Levetiracetam has not changed his events and has made him irritable; with epilepsy excluded it should be withdrawn. **S**
   - Levetiracetam 250 mg twice daily for two weeks, 250 mg at night for one week, then stop.
4. **Generalized anxiety disorder** (F41.1). GAD-7 13; worry about his future, health, and studies with restlessness and poor sleep. **S**
   - Addressed within the psychotherapy; reassess with GAD-7 at each visit.
5. **Major depressive disorder, single episode, moderate** (F32.1). PHQ-9 12, item 9 scored 0; no history of mania or hypomania on interview. Psychotherapy first; an SSRI will be offered if symptoms persist. **S**
   - Safety plan reviewed and unchanged; 988 Suicide & Crisis Lifeline and clinic number confirmed.
   - PHQ-9 and GAD-7 at every visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PHQ-9 | Baseline, then at least monthly during acute treatment; every 2 to 4 weeks in continuation | Completed today | 12, down from 13; item 9 scored 0 |
| Survey | GAD-7 | With the PHQ-9 when anxiety accompanies depression | Completed today | 13, down from 14 |
| Survey | Suicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9) | Every visit during active treatment | Completed today | No suicidal thoughts, intent, plan, or behavior; rifle locked with ammunition separate; protective factors unchanged |
| Survey | Bipolar screen at the initial depression workup | Once, at the initial workup | Completed today | No past manic or hypomanic episode on interview; no Mood Disorder Questionnaire score recorded |
| Imaging | Video-EEG monitoring to capture habitual events | Once, to establish the diagnosis | Completed today | Two habitual events with a normal EEG throughout; normal interictal EEG; ILAE 'documented' level |
| Imaging | Brain MRI with an epilepsy protocol | Once, in the diagnostic workup | Completed today | Normal, last week |
| Examination | Event diary: frequency, duration, triggers, warning sensations, and injuries | Every visit | Completed today | Two or three events a month before admission; two recorded on the unit |
| Medication safety | Antiseizure medicine review | At diagnosis and until withdrawn | Completed today | Levetiracetam without benefit and with irritability; taper over three weeks begins today |
| Medication safety | SSRI tolerability check two weeks after starting | 2 weeks after starting and after each dose change | Not indicated | No antidepressant started; psychotherapy first |
| Referral | Neurology consultation (epilepsy and functional neurological disorder) | For recurrent events of uncertain cause | Completed today | Seen on the unit; diagnosis made and explained |
| Referral | CBT-informed psychotherapy for functional seizures | Once the diagnosis is accepted | Ordered | Twelve weekly sessions starting in two weeks |
| Self-management | Driving | Every visit until cleared | Completed today | Not driving; not during the taper; may resume after at least three months free of events, with the neurologist's agreement |
| Self-management | Sleep, studies, and first-aid plan | Every visit | Completed today | Fixed bedtime with at least seven hours; first-aid card for friends and his tutoring workplace |
| Laboratory | Lithium, anticonvulsant mood-stabilizer, or antipsychotic monitoring | Only on those drugs | Not indicated | Not taking any; no bipolar features |

## Goal progress

- Cause of the episodes established by the second visit. Outcome by 1774-04-30: Functional/dissociative seizures documented by video-EEG; epilepsy and syncope excluded. **S**
- Antiseizure medicine stopped safely. In progress; target 1774-06-11. **S**
- Events reduced by at least half, then free of events for three months. In progress; target 1774-12-31. **S**
- Depression and anxiety improved by at least 50 percent (PHQ-9 and GAD-7). In progress; target 1774-12-31. **S**
- No suicidal thoughts. In progress; target 1774-12-31. **S**

## Medication changes

- Stopped: Levetiracetam 500 mg oral tablet, one tablet twice daily, started at an emergency department visit four months before intake for possible seizures, without an EEG **S**
- Started: Levetiracetam 500 mg oral tablet, taper: half a tablet (250 mg) twice daily for two weeks, then half a tablet at night for one week, then stop **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge
- LaFrance WC Jr, et al. Minimum requirements for the diagnosis of psychogenic nonepileptic seizures: a staged approach: a report from the International League Against Epilepsy Nonepileptic Seizures Task Force. Epilepsia 2013;54(11):2005-2018 (PMID 24111933) (2013), International League Against Epilepsy
- Hingray C, et al. Functional/dissociative seizures: Proposal for a new diagnostic label and definition by the ILAE task force. Epilepsia 2025;66(11):4162-4182 (PMID 40884444) (2025), International League Against Epilepsy
- Fisher RS, et al. Operational classification of seizure types by the International League Against Epilepsy. Epilepsia 2017;58(4):522-530 (PMID 28276060) (2017), International League Against Epilepsy
- Hall-Patch L, et al. Acceptability and effectiveness of a strategy for the communication of the diagnosis of psychogenic nonepileptic seizures. Epilepsia 2010;51(1):70-78 (PMID 19453708) (2010), Epilepsia (International League Against Epilepsy)
- Stone J, et al. Explanation as treatment for functional neurologic disorders. Handb Clin Neurol 2016;139:543-553 (PMID 27719870) (2016), Handbook of Clinical Neurology (Elsevier)
- LaFrance WC Jr, et al. Multicenter pilot treatment trial for psychogenic nonepileptic seizures: a randomized clinical trial. JAMA Psychiatry 2014;71(9):997-1005 (PMID 24989152) (2014), JAMA Psychiatry
- Goldstein LH, et al. Cognitive behavioural therapy for adults with dissociative seizures (CODES): a pragmatic, multicentre, randomised controlled trial. Lancet Psychiatry 2020;7(6):491-505 (PMID 32445688) (2020), Lancet Psychiatry
- Tolchin B, et al. Seizures, Driver Licensure, and Medical Reporting Update: An AAN Position Statement. Neurology 2025;104(7):e213459 (PMID 40073306) (2025), American Academy of Neurology, American Epilepsy Society, and Epilepsy Foundation of America
- VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022), United States Department of Veterans Affairs and Department of Defense
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense

## Follow-up

- Six-week review; psychotherapy starts in two weeks; call sooner for events that differ from his usual ones, injury, or any thoughts of self-harm. **S**
- Next scheduled visit 1774-06-11: six-week review after the diagnosis: levetiracetam withdrawn, psychotherapy under way, mood and anxiety. **S**
